Acceleron Pharma

Investors/Media

Press Releases

Date Title and Summary View
Toggle Summary Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting
– Multiple patients continue on treatment with clinically meaningful increases in hemoglobin and reduction in red blood cell transfusions surpassing 3 years – – Top-line results from the MEDALIST Phase 3 trial are on track for the middle of 2018 – – COMMANDS Phase 3 trial in first-line, lower-risk
View HTML
Toggle Summary Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension
PULSAR trial expands Acceleron’s pipeline into pulmonary disease CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 22, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced
View HTML
Toggle Summary Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 17, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver three presentations on luspatercept at the 23 rd
View HTML
Toggle Summary Acceleron Reports First Quarter 2018 Operating and Financial Results
– Top-line results from the MEDALIST and BELIEVE Phase 3 trials of luspatercept expected in mid-2018 – – ACE-083 advances into Part 2 of the ongoing Phase 2 trial in facioscapulohumeral muscular dystrophy – – PULSAR Phase 2 trial with sotatercept in pulmonary arterial hypertension on track to
View HTML
Toggle Summary Acceleron to Participate in Two Healthcare Investor Conferences in May
CAMBRIDGE,Mass.--(BUSINESS WIRE)--May 2, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare
View HTML
Toggle Summary Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy (FSHD)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 1, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the U.S. Food and Drug Administration ( FDA ) has granted
View HTML
Toggle Summary Acceleron to Webcast First Quarter 2018 Operating and Financial Results on May 8, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 30, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, May 8, 2018 at 5:00 p.m. EDT to discuss its first quarter 2018 operating and financial results.
View HTML
Toggle Summary Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting
– Oral presentation to highlight preliminary results of ACE-083’s Phase 2 trial in patients with facioscapulohumeral muscular dystrophy – – Part 2 of the ongoing Phase 2 trial in patients with facioscapulohumeral muscular dystrophy has been initiated – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr.
View HTML
Toggle Summary Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 26, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that two abstracts on lead product candidate luspatercept will
View HTML
Toggle Summary Acceleron to Host Educational Webinar with Leading Clinicians to Provide an Overview of Pulmonary Arterial Hypertension (PAH) and the Sotatercept Phase 2 Trial
- Educational webinar to be held on Wednesday, March 28 th at 8:00 a.m. EDT - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 12, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases,
View HTML